Insmed (INSM) Return on Capital Employed (2011 - 2026)
Insmed's (INSM) quarterly Return on Capital Employed came in at 63.67% in Q1 2026, down 510.0% year-on-year from 15.53% in Q1 2025, and up 5.84% quarter-over-quarter from 67.62% in Q4 2025.
Insmed (INSM) Return on Capital Employed (2011 - 2026) Analysis & Trends
Insmed's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 63.67% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 510.0% year-over-year to 63.67% in Q1 2026; TTM through Mar 2026 was 63.67%, a 510.0% decrease from a year earlier, with the FY2025 full-year figure at 74.39%, down 1075.0% from the prior year.
- Return on Capital Employed rose to 63.67% in Q1 2026 per INSM's latest filing, from 67.62% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.51% in Q1 2022 and bottomed at 85.84% in Q1 2024.
- The 5-year median for Return on Capital Employed is 54.92% (2025), against an average of 55.19%.
- Across the five-year window, Return on Capital Employed plunged 4898 bps in 2024 and soared 2727 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 40.28% in 2022, then plunged by 60 bps to 64.41% in 2023, then rose by 22 bps to 50.43% in 2024, then sank by 34 bps to 67.62% in 2025, then increased by 6 bps to 63.67% in 2026.
- Per Business Quant, the three latest INSM Return on Capital Employed figures stand at 63.67% (Q1 2026), 67.62% (Q4 2025), and 57.78% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Insmed | 22.60 Bn | 21.38 Bn | 258.54 Mn | -63.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.67% |
| Dec 31, 2025 | -67.62% |
| Sep 30, 2025 | -57.78% |
| Jun 30, 2025 | -54.92% |
| Mar 31, 2025 | -58.57% |
| Dec 31, 2024 | -50.43% |
| Sep 30, 2024 | -49.40% |
| Jun 30, 2024 | -79.17% |
| Mar 31, 2024 | -85.84% |
| Dec 31, 2023 | -64.41% |
| Sep 30, 2023 | -57.61% |
| Jun 30, 2023 | -52.02% |
| Mar 31, 2023 | -36.86% |
| Dec 31, 2022 | -40.28% |
| Sep 30, 2022 | -45.68% |
| Jun 30, 2022 | -38.49% |
| Mar 31, 2022 | -35.51% |
| Dec 31, 2021 | -32.83% |
| Sep 30, 2021 | -31.99% |
| Jun 30, 2021 | -37.51% |